Brain Activity of Benzoate, a D-Amino Acid Oxidase Inhibitor, in Patients With Mild Cognitive Impairment in a Randomized, Double-Blind, Placebo Controlled Clinical Trial | Zendy

HsienYuan Lane | Zendy; ChengHao Tu | Zendy; Wei-Che Lin | Zendy; ChiehHsin Lin | Zendy

Open Access

Brain Activity of Benzoate, a D-Amino Acid Oxidase Inhibitor, in Patients With Mild Cognitive Impairment in a Randomized, Double-Blind, Placebo Controlled Clinical Trial

Author(s) -

HsienYuan Lane,

ChengHao Tu,

Wei-Che Lin,

ChiehHsin Lin

Publication year - 2021

Publication title -

the international journal of neuropsychopharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 107

eISSN - 1469-5111

pISSN - 1461-1457

DOI - 10.1093/ijnp/pyab001

Subject(s) - placebo , psychology , functional magnetic resonance imaging , dementia , lingual gyrus , medicine , audiology , neuroscience , pathology , disease , alternative medicine

Current anti-dementia drugs cannot benefit mild cognitive impairment (MCI). Sodium benzoate (a D-amino acid oxidase [DAO] inhibitor) has been found to improve the cognitive function of patients with early-phase Alzheimer's disease (mild Alzheimer's disease or MCI). However, its effect on brain function remains unknown. This study aimed to evaluate the influence of benzoate on functional magnetic resonance imaging in patients with amnestic MCI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research